Rocket Pharmaceuticals, Inc. Proceeds from Sale of Intangible Assets
Rocket Pharmaceuticals, Inc. (RCKT) reported Proceeds from Sale of Intangible Assets of $180.00 million for the 1-month period ending 2026-04-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2026-08-10
- 2026-04-30: Proceeds from Sale of Intangible Assets 1 month $180.00M.
| Period end | Proceeds from Sale of Intangible Assets 1 month |
|---|---|
| 2026-04-30 | $180.00M 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |